Quit Smoking Drugs Market Report 2026

Quit Smoking Drugs Market Overview

• Quit Smoking Drugs market size has reached to $44.23 billion in 2025 • Expected to grow to $90.73 billion in 2030 at a compound annual growth rate (CAGR) of 15.5% • Growth Driver: Rising Addiction Linked To Smoking Fuels Growth In Quit-Smoking Drug Market • Market Trend: Medicated Products To Address The Unacceptably High Death Burden • North America was the largest region in 2025.

What Is Covered Under Quit Smoking Drugs Market?

Quit smoking drugs are special drugs that individuals use in quitting smoking and that decrease craving and other nicotine withdrawal symptoms. It is used to deliver nicotine in an alternate form, such as chewing gum or patches, for a brief period, which lessens the withdrawal symptoms from nicotine and the urge to smoke. The major products of quit-smoking drugs are drug therapy, electronic cigarettes, nicotine inhalers, nicotine replacement therapies, and nicotine sublingual tablets. Drug therapy refers to the administration of drugs to treat or prevent disease. Drugs such as Varenicline (Chantix), Bupropion (Zyban), and others are available in drug stores, online pharmacies, and retail pharmacies.

What Is The Quit Smoking Drugs Market Growth Forecast?

The quit smoking drugs market size is expected to see rapid growth in the next few years. It will grow to $90.73 billion in 2030 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to advancement in digital health solutions, rising adoption of personalized medicine, integration of ai in treatment monitoring, expansion of telemedicine services, growth of wearable health monitoring devices. Major trends in the forecast period include personalized nicotine replacement therapies, mobile health (mhealth) & smoking cessation apps, telemedicine-driven prescription support, behavioral therapy integration with drug therapy, wearable devices for monitoring cravings.

What Is The Driver Of The Quit Smoking Drugs Market?

The growing prevalence of smoking addiction is expected to propel the growth of the quit-smoking drug market going forward. Smoking is the practice of inhaling and exhaling burning plant material vapors such as marijuana and hashish, tobacco, and others. Quit smoking drugs are used to reduce the urge to smoke by hampering the craving for tobacco in an individual, where they are used as prescription medications to control nicotine withdrawal symptoms to aid in quitting smoking effectively. For instance, in November 2025, according to the OECD (Organisation for Economic Co-operation and Development), a France-based intergovernmental international organization, 14.8% of people aged 15 and over smoked daily in 2023. The proportion of daily smokers was highest in Türkiye, Hungary, and Greece, as well as in accession/partner countries Indonesia, Bulgaria, and China, where at least one in four people smoked daily. On average, 18.5% of men smoked daily in 2023 compared to 11.4% of women. Therefore, the growing prevalence of smoking addiction is driving the growth of the quit-smoking drug market.

Key Players In The Global Quit Smoking Drugs Market

Major companies operating in the quit smoking drugs market are 22nd Century Group, Cipla Limited, Dr. Reddy's Laboratories, GSK Plc., Johnson & Johnson, NJOY LLC, Perrigo Company Plc, Pfizer Inc., Philip Morris International, Glenmark Pharmaceuticals Limited, Zydus Cadila Healthcare Limited, BioCorRx Inc., Ennaid Therapeutics LLC, Fertin Pharma A/S, Hikma Pharmaceuticals PLC, IntelGenx Technologies Corp., Innovus Pharmaceuticals Inc., Gilla Inc., Rusan Pharma Ltd., Novartis AG

Global Quit Smoking Drugs Market Trends and Insights

Major companies operating in the quit smoking drugs market are focusing on the development of new formulations and delivery methods, such as generic tablets, to expand market leadership across regions and gain a competitive edge. Generic varenicline tablets are non-branded versions of the medication containing varenicline tartrate, which are bioequivalent to the original branded product and used for smoking cessation therapy. For instance, in January 2024, Lupin Limited, an India-based pharmaceutical company, launched new Varenicline tablets in the United States, available in 0.5 mg and 1 mg strengths. These tablets are the generic versions of Chantix tablets (0.5 mg and 1 mg) from PF Prism C.V. and are used to assist in smoking cessation treatment. As a partial agonist of the nicotinic acetylcholine receptor, varenicline works by stimulating the release of dopamine, which can alleviate withdrawal symptoms and cravings associated with nicotine addiction. This dual mechanism allows it to reduce the pleasurable effects of smoking while providing some stimulation to minimize withdrawal effects.

What Are Latest Mergers And Acquisitions In The Quit Smoking Drugs Market?

In September 2024, Dr. Reddy's Laboratories, an India-based pharmaceutical company, acquired the nicotine replacement therapy business from Haleon plc for $680 million (£500 million). The aim of the acquisition is to strengthen Dr. Reddy's position in the global consumer healthcare market, particularly by enhancing its over-the-counter (OTC) offerings and expanding its presence in key international markets outside the United States. Haleon plc is a UK-based consumer health company that specializes in nicotine addiction drugs.

What Defines the Quit Smoking Drugs Market?

The quit-smoking drugs market consists of sales of AXS-05, cytisincline, nadolol, and liraglutide. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Quit Smoking Drugs Market Report 2026?

The quit smoking drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the quit smoking drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.